OTCMKTS:GENTY - Gentium Srl Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
Previous Close$56.10
Today's RangeN/A
52-Week Range$7.26 - $59.25
VolumeN/A
Average Volume6,528 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Gentium SpA is a biopharmaceutical company focused on the development and manufacture of its product candidate, defibrotide, an investigational drug based on a mixture of single-stranded and double-stranded deoxyribonucleic acid (DNA) extracted from pig intestines. The Company's development of defibrotide has been focused on the treatment and prevention of a disease called hepatic veno-occlusive disease ( VOD), a condition that occurs when veins in the liver are blocked as a result of cancer treatments, such as chemotherapy or radiation, that are administered prior to stem cell transplantation. In February 2014, Jazz Pharmaceuticals PLC acquired the 98% interest in Gentium SpA (Gentium).

Receive GENTY News and Ratings via Email

Sign-up to receive the latest news and ratings for GENTY and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorN/A
Current SymbolOTCMKTS:GENTY
CUSIPN/A
CIKN/A
Phone+39-31-5373200

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable

Gentium Srl (OTCMKTS:GENTY) Frequently Asked Questions

What is Gentium Srl's stock symbol?

Gentium Srl trades on the OTCMKTS under the ticker symbol "GENTY."

Has Gentium Srl been receiving favorable news coverage?

Headlines about GENTY stock have trended neutral this week, InfoTrie reports. The research firm scores the sentiment of press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Gentium Srl earned a news impact score of 0.4 on InfoTrie's scale. They also assigned news coverage about the biopharmaceutical company a news buzz of 6.0 out of 10, meaning that recent press coverage is somewhat likely to have an impact on the stock's share price in the immediate future.

Who are Gentium Srl's key executives?

Gentium Srl's management team includes the folowing people:
  • Khalid Islam Ph.D., Chairman of the Board, Chief Executive Officer, Interim Scientific Director (Age 61)
  • Salvatore Calabrese, Chief Financial Officer, Chief Operating Officer (Age 44)
  • Carin Heringa, Senior Vice President, Scientific Director (Age 52)
  • Marco Maria Brughera, Director (Age 60)
  • Laura Ferro Ph.D., Director (Age 62)
  • Gigliola Bertoglio CPA, Independent Director (Age 79)
  • Bobby W. Sandage Jr., Ph.D., Independent Director (Age 63)
  • Elmar J. Schnee, Independent Director (Age 57)

How do I buy shares of Gentium Srl?

Shares of GENTY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Gentium Srl's official website?

The official website for Gentium Srl is https://www.gentium.com/.

How can I contact Gentium Srl?

Gentium Srl's mailing address is Piazza XX Settembre, 2, VILLA GUARDIA, 22079, Italy. The biopharmaceutical company can be reached via phone at +39-31-5373200.


MarketBeat Community Rating for Gentium Srl (OTCMKTS GENTY)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  106 (Vote Outperform)
Underperform Votes:  69 (Vote Underperform)
Total Votes:  175
MarketBeat's community ratings are surveys of what our community members think about Gentium Srl and other stocks. Vote "Outperform" if you believe GENTY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GENTY will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/19/2019 by MarketBeat.com Staff

Featured Article: What is Put Option Volume?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel